Timothy Rogers - Alterola Biotech Ex CFO

All Insiders . USA . 
Stock . Alterola Biotech . Stakeholders . Insider . Timothy Rogers
ABTI Stock  USD 0.01  0  25.00%   

Insider

Timothy Rogers is Ex CFO of Alterola Biotech
Age 59
Phone44 1516 019 477
Webhttps://alterola-abti.com

Alterola Biotech Management Efficiency

The company has return on total asset (ROA) of (0.6669) % which means that it has lost $0.6669 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2729) %, meaning that it created substantial loss on money invested by shareholders. Alterola Biotech's management efficiency ratios could be used to measure how well Alterola Biotech manages its routine affairs as well as how well it operates its assets and liabilities.
Alterola Biotech currently holds 251.18 K in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Alterola Biotech has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Alterola Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Alterola Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Alterola Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Alterola to invest in growth at high rates of return. When we think about Alterola Biotech's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

BComm BComAkanda Corp
68
Alex DasallaCollegium Pharmaceutical
N/A
Erica CPABiofrontera
39
Raymond CoffmancbdMD Inc
62
Advocate OhayonINC Research Holdings
35
OriMoni MimonINC Research Holdings
36
Tejinder VirkAkanda Corp
42
Hermann LubbertBiofrontera
68
Sandra BeaverEvolus Inc
46
Richard MDCollegium Pharmaceutical
64
Marlo ManningCollegium Pharmaceutical
N/A
John WestoncbdMD Inc
N/A
David EricksonEvolus Inc
N/A
Sibyl SwiftcbdMD Inc
43
Rami LevyINC Research Holdings
59
Muthusamy RPhANI Pharmaceuticals
56
Elizabeth JDANI Pharmaceuticals
N/A
Eugene IIIBiofrontera
39
Amos CohenINC Research Holdings
45
Thomas FlowAkanda Corp
46
CCFP DipSportMedEvolus Inc
60
Alterola Biotech, Inc., a pharmaceutical company, engages in the development of cannabinoid and cannabinoid-like molecules. It focuses on the development of regulated human and animal health pharmaceuticals and regulated food products production of active pharmaceutical ingredients and food-grade ingredients and formulation and drug delivery for improved bioavailability, solubility, and stability. Alterola Biotech is traded on OTC Exchange in the United States. Alterola Biotech [ABTI] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

Return On Equity-1.27
Return On Asset-0.67

Alterola Biotech Leadership Team

Elected by the shareholders, the Alterola Biotech's board of directors comprises two types of representatives: Alterola Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alterola. The board's role is to monitor Alterola Biotech's management team and ensure that shareholders' interests are well served. Alterola Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alterola Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Colin BSc, COO Director
Timothy Rogers, Ex CFO
Seamus McAuley, S Director
David OBE, CEO Director
Hunter Land, VP Director
Dominic Schiller, Chief Counsel

Alterola Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Alterola Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-1.27
Return On Asset-0.67
Current Valuation68.08 M
Shares Outstanding807.05 M
Price To Book6.29 X
EBITDA(6.47 M)
Net Income(6.47 M)
Cash And Equivalents61.54 K
Total Debt251.18 K
Debt To Equity0.02 %

Currently Active Assets on Macroaxis

VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C
MSFTMicrosoft
GMGeneral Motors

Other Information on Investing in Alterola Pink Sheet

Alterola Biotech financial ratios help investors to determine whether Alterola Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Alterola with respect to the benefits of owning Alterola Biotech security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY